Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Net Margin (2016 - 2025)

Historic Net Margin for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to 33.42%.

  • Cytosorbents' Net Margin fell 12800.0% to 33.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.77%, marking a year-over-year increase of 270700.0%. This contributed to the annual value of 58.21% for FY2024, which is 358800.0% up from last year.
  • Latest data reveals that Cytosorbents reported Net Margin of 33.42% as of Q3 2025, which was down 12800.0% from 20.25% recorded in Q2 2025.
  • Cytosorbents' 5-year Net Margin high stood at 20.25% for Q2 2025, and its period low was 150.42% during Q3 2022.
  • Moreover, its 5-year median value for Net Margin was 65.64% (2021), whereas its average is 63.09%.
  • Data for Cytosorbents' Net Margin shows a peak YoY increase of 781600bps (in 2022) and a maximum YoY decrease of -891600bps (in 2022) over the last 5 years.
  • Cytosorbents' Net Margin (Quarter) stood at 86.32% in 2021, then surged by 91bps to 8.16% in 2022, then plummeted by -725bps to 67.31% in 2023, then dropped by -23bps to 82.69% in 2024, then surged by 60bps to 33.42% in 2025.
  • Its Net Margin stands at 33.42% for Q3 2025, versus 20.25% for Q2 2025 and 16.94% for Q1 2025.